GLP-1 agonists, including exenatide, liraglutide, lixisenatide, albiglutide, and taspoglutide can stimulate insulin secretion (similar to other insulin secretagogues), improve peripheral insulin resistance, decrease body weight, and reduce the risk of hypoglycemia for Type 2 diabetic patients [63]. The gene discussed is INS; the disease is Hypoglycemia.